48-Week Off-Therapy Efficacy and Safety of Bulevirtide in Combination with Pegylated Interferon Alfa-2A in Patients with Chronic Hepatitis Delta: Final Results from the Phase 2b, Openlabel, Randomised, Multicentre Study MYR204
JOURNAL OF HEPATOLOGY(2024)
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined